HR 4385
115th Congress
House
Health
Drug safety, medical device, and laboratory regulation
Marketing and advertising
Prescription drugs
Responsibility in Drug Advertising Act of 2017
Introduced: November 14, 2017
Introduced by:
DeLauro, Rosa L.
Democratic
· Connecticut
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 17, 2017
Referred to the Subcommittee on Health.
Nov 14, 2017
Referred to the House Committee on Energy and Commerce.
Nov 14, 2017
Introduced in House
Plain-English summary
Responsibility in Drug Advertising Act of 2017
This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may: (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2